Registro completo de metadatos
| Campo DC | Valor | Lengua/Idioma |
|---|---|---|
| dc.creator | Díaz Bessone, María Inés | - |
| dc.creator | Berardi, Damian Emilio | - |
| dc.creator | Campodónico, Paola Bernadette | - |
| dc.creator | Todaro, Laura Beatriz | - |
| dc.creator | Lothstein, Leonard | - |
| dc.creator | Bal, Elisa Dora | - |
| dc.creator | Urtreger, Alejandro Jorge | - |
| dc.date | 2019-01-03T13:13:22Z | - |
| dc.date | 2019-01-03T13:13:22Z | - |
| dc.date | 2011-04 | - |
| dc.date | 2019-01-02T19:57:17Z | - |
| dc.date.accessioned | 2019-04-29T15:53:25Z | - |
| dc.date.available | 2019-04-29T15:53:25Z | - |
| dc.date.issued | 2011-04 | - |
| dc.identifier | Díaz Bessone, María Inés; Berardi, Damian Emilio; Campodónico, Paola Bernadette; Todaro, Laura Beatriz; Lothstein, Leonard; et al.; Involvement of PKC delta (PKCδ) in the resistance against different doxorubicin analogs; Springer; Breast Cancer Research and Treatment; 126; 3; 4-2011; 577-587 | - |
| dc.identifier | 0167-6806 | - |
| dc.identifier | http://hdl.handle.net/11336/67272 | - |
| dc.identifier | CONICET Digital | - |
| dc.identifier | CONICET | - |
| dc.identifier.uri | http://rodna.bn.gov.ar:8080/jspui/handle/bnmm/304747 | - |
| dc.description | Doxorubicin is an anti-tumor antibiotic widely used in the management of cancer patients. Its main mechanism of action involves the generation of DNA damage and the inhibition of topoisomerase II, promoting apoptosis. AD 198 is a novel doxorubicin analog devoid of DNA binding and topoisomerase II inhibitory capacities. It has been proposed that AD 198 induces apoptosis by activating protein kinase C delta (PKCδ); a PKC isoform described as growth inhibitory in a large number of cell types. We have previously demonstrated that PKCδ over-expression in NMuMG cells induced the opposite effect, promoting proliferation and cell survival. In this study, we found that PKCδ overexpression confers an enhanced cell death resistance against AD 198 cytotoxic effect and against AD 288, another doxorubicin analog that preserves its mechanism of action. These resistances involve PKCδ-mediated activation of two well-known survival pathways: Akt and NF-κB. While the resistance against AD 198 could be abrogated upon the inhibition of either Akt or NF-κB pathways, only NF-κB inhibition could revert the resistance to AD 288. Altogether, our results indicate that PKCδ increases cell death resistance against different apoptosis inductors, independently of their mechanism of action, through a differential modulation of Akt and NF-κB pathways. Our study contributes to a better understanding of the mechanisms involved in PKCδ-induced resistance and may greatly impact in the rationale design of isozyme-specific PKC modulators as therapeutic agents. © Springer Science+Business Media, LLC. 2010. | - |
| dc.description | Fil: Díaz Bessone, María Inés. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina. Universidad de Buenos Aires. Facultad de Medicina. Instituto de Oncología "Ángel H. Roffo"; Argentina | - |
| dc.description | Fil: Berardi, Damian Emilio. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina. Universidad de Buenos Aires. Facultad de Medicina. Instituto de Oncología "Ángel H. Roffo"; Argentina | - |
| dc.description | Fil: Campodónico, Paola Bernadette. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina. Universidad de Buenos Aires. Facultad de Medicina. Instituto de Oncología "Ángel H. Roffo"; Argentina | - |
| dc.description | Fil: Todaro, Laura Beatriz. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina. Universidad de Buenos Aires. Facultad de Medicina. Instituto de Oncología "Ángel H. Roffo"; Argentina | - |
| dc.description | Fil: Lothstein, Leonard. The University of Tennessee Health Science Center and Center for Cancer Research; Estados Unidos | - |
| dc.description | Fil: Bal, Elisa Dora. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina. Universidad de Buenos Aires. Facultad de Medicina. Instituto de Oncología "Ángel H. Roffo"; Argentina | - |
| dc.description | Fil: Urtreger, Alejandro Jorge. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina. Universidad de Buenos Aires. Facultad de Medicina. Instituto de Oncología "Ángel H. Roffo"; Argentina | - |
| dc.format | application/pdf | - |
| dc.format | application/pdf | - |
| dc.language | eng | - |
| dc.publisher | Springer | - |
| dc.relation | info:eu-repo/semantics/altIdentifier/doi/https://dx.doi.org/10.1007/s10549-010-0956-2 | - |
| dc.relation | info:eu-repo/semantics/altIdentifier/url/https://link.springer.com/article/10.1007/s10549-010-0956-2 | - |
| dc.rights | info:eu-repo/semantics/restrictedAccess | - |
| dc.rights | https://creativecommons.org/licenses/by-nc-sa/2.5/ar/ | - |
| dc.source | reponame:CONICET Digital (CONICET) | - |
| dc.source | instname:Consejo Nacional de Investigaciones Científicas y Técnicas | - |
| dc.source | instacron:CONICET | - |
| dc.source.uri | 9-2016 | - |
| dc.subject | AD 198 | - |
| dc.subject | AD 288 | - |
| dc.subject | CELL DEATH RESISTANCE | - |
| dc.subject | PKCΔ | - |
| dc.subject | Salud Ocupacional | - |
| dc.subject | Ciencias de la Salud | - |
| dc.subject | CIENCIAS MÉDICAS Y DE LA SALUD | - |
| dc.title | Involvement of PKC delta (PKCδ) in the resistance against different doxorubicin analogs | - |
| dc.type | info:eu-repo/semantics/article | - |
| dc.type | info:eu-repo/semantics/publishedVersion | - |
| dc.type | info:ar-repo/semantics/articulo | - |
| Aparece en las colecciones: | CONICET | |
Ficheros en este ítem:
No hay ficheros asociados a este ítem.